Abstract Background The zero-COVID policy and non-pharmaceutical interventions (NPIs) implemented in response to COVID-19 concurrently influenced the transmission of other respiratory pathogens. In the post-pandemic era following the policy’s cessation, whether the epidemiological patterns of these respiratory pathogens have reverted to pre-pandemic baselines or persisted unchanged remains a subject of interest. Methods The retrospective study analyzed 8,774 cases with acute respiratory tract infections (ARTIs) from 2022 to 2024, with data sourced from 26 children’s hospitals or general hospitals in Hunan Province, to investigate the potential impacts of policy changes on epidemiology. Nine common respiratory pathogens were detected using targeted next-generation sequencing (tNGS) technology. Results Among children seeking medical care, the overall pathogen positive rate increased ( P < 0.001) in both 2023 and 2024, primarily affecting children aged ≤ 1 year and those ≥ 6 years. The positivity rate of respiratory syncytial virus (RSV, both RSV-A and RSV-B) in children aged ≤ 3 years increased and resumed its winter-spring seasonality in 2023–2024, with RSV-A predominant in 2023 and RSV-B in 2024. Human metapneumovirus (HMPV) showing a counter-seasonal pattern. The seasonal epidemics of human parainfluenza virus (HPIV) (mainly HPIV-3) and human bocavirus (HBoV) occur earlier in summer. Influenza A virus (FluA) established typical circulation pattern with influenza B virus (FluB) in autumn and winter. The positive rate of single infection and co-infection of pathogens increased ( P < 0.01). The negative co-occurrence patterns between viruses are common. The restricted cubic spline (RCS) model indicates that the susceptible populations for RSV, HMPV, HPIV, and FluA have changed. Conclusion With the end of the Zero-COVID policy, some respiratory pathogens, including RSV, HPIV, HBoV, and Flu, show clear seasonality. Clinics should closely monitor the epidemiological trends of pediatric respiratory pathogens in the post-pandemic period. Clinical trial number Not applicable. This study is a retrospective analysis based on clinical data. Since it only involves statistical analysis and no clinical trials, a clinical trial number is not required.
Long et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: